Market research
LOGC Contextlogic Inc
OTCQB USD Consumer Cyclical
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 707M
- P/E ratio
- Not available
- Analyst target
- 5.9
- Dividend yield
- Not available
- Beta
- 2.04
Profile
Instrument facts
- Exchange
- OTCQB
- Currency
- USD
- Sector
- Consumer Cyclical
- Industry
- Internet Retail
- ISIN
- Not available
- Market cap
- 707M
- P/E ratio
- Not available
- Analyst target
- 5.9
- Dividend yield
- Not available
- Beta
- 2.04
About
About Contextlogic Inc
ContextLogic Holdings Inc. focuses on seeking to develop and grow a de novo business and finance potential future bolt-on acquisitions of assets or businesses. The company was incorporated in 2010 and is headquartered in Oakland, California.
Research context
Contextlogic Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Consumer Cyclical
- Industry
- Internet Retail
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the LOGC discussion.
5 years, 7 months ago
LogicBio Therapeutics, Inc is currently in a long term downtrend where the price is trading 38.2% below its 200 day moving average.
From a valuation standpoint, the stock is 96.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 52.6.
LogicBio Therapeutics, Inc's total revenue rose by inf% to $542K since the same quarter in the previous year.
Its net income has increased by 39.8% to $-7M since the same quarter in the previous year.
Finally, its free cash flow grew by 36.7% to $-8M since the same quarter in the previous year.
Based on the above factors, LogicBio Therapeutics, Inc gets an overall score of 4/5.